What Is Allergy Immunotherapy? An Educational Overview

Allergy immunotherapy is sometimes loosely called an allergy vaccine, and the comparison captures the basic idea: both train the immune system through controlled exposure. But there are important differences. A traditional vaccine prompts the immune system to mount a stronger, protective response against a germ. Allergy immunotherapy does the opposite, teaching the immune system to react less, to tolerate an allergen it currently overreacts to. It also works gradually over years of repeated dosing rather than in a few shots. So while the vaccine analogy helps explain the concept of immune education, immunotherapy is really a desensitization treatment, and it should not be thought of as a one-time preventive shot.

Allergy immunotherapy is best established for inhaled, environmental allergies. These include allergic rhinitis and conjunctivitis caused by tree, grass, and weed pollens, dust mites, mold, and animal dander. It is also a well-proven treatment for severe allergy to stinging insect venom. Immunotherapy is not a standard treatment for most food allergies through the sublingual or injected routes, though oral immunotherapy is a separate, specialized approach for certain foods, and food sublingual immunotherapy remains investigational with weaker evidence. It is also not used for non-allergic conditions that can mimic allergy. A clinician confirms through testing and history whether your specific condition is one that immunotherapy can realistically help.

Allergy immunotherapy has solid evidence for reducing symptoms and medication needs in allergic rhinitis, though effectiveness varies between people and between the two delivery routes. Allergy shots have the longest and strongest evidence base. For sublingual immunotherapy, a large 2013 systematic review in JAMA found moderate-grade evidence of symptom reduction across many randomized trials. Importantly, no form of immunotherapy is a guaranteed cure, and benefits depend heavily on completing a full multi-year course. Some people experience lasting relief that continues after treatment ends, while others see partial improvement. Setting realistic expectations with your clinician, and committing to consistent dosing, gives immunotherapy the best chance of meaningful results.

Immunotherapy is not appropriate for everyone. People with uncontrolled or severe asthma face higher risks and are generally not started until their asthma is well managed. Those with certain heart conditions or on specific medications, such as some beta-blockers, may need careful evaluation because of how a serious reaction would be treated. Pregnancy is usually not the time to begin a new course, although established treatment may sometimes continue. Eosinophilic esophagitis is a specific contraindication for sublingual immunotherapy. Very young children and people who cannot commit to years of consistent treatment may also not be ideal candidates. A board-certified allergist weighs these factors individually before recommending immunotherapy.

Allergy immunotherapy can help allergic asthma when the asthma is triggered by specific allergens such as dust mites or pollen, and it is often used alongside, not instead of, standard asthma controller medications. By reducing the allergic sensitization that drives airway inflammation, immunotherapy may lessen symptoms and medication needs over time, and some studies suggest treating allergic rhinitis with immunotherapy can reduce the risk of progressing to asthma. The important caveat is that uncontrolled or severe asthma is a contraindication, because a reaction to treatment could be more dangerous in someone whose airways are unstable. Asthma must be well managed before starting, and immunotherapy is not a rescue treatment for an asthma attack. Decisions are individualized with your clinician.